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Background: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling
pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pan-
creatic cancer models. In this study, rigosertib was assessed in combination with gemcitabine in patients with treatment-
naïve metastatic pancreatic adenocarcinoma.
Materials and methods: Patients with metastatic pancreatic adenocarcinoma were randomized in a 2:1 fashion to
gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4-week cycle plus rigosertib 1800 mg/m2 via 2-h continuous IV infu-
sions given twice weekly for 3 weeks of a 4-week cycle (RIG + GEM) versus gemcitabine 1000 mg/m2 weekly for 3 weeks
in a 4-week cycle (GEM).
Results: A total of 160 patients were enrolled globally and randomly assigned to RIG + GEM (106 patients) or GEM (54).
The most common grade 3 or higher adverse events were neutropenia (8% in the RIG + GEM group versus 6% in the
GEM group), hyponatremia (17% versus 4%), and anemia (8% versus 4%). The median overall survival was 6.1 months
for RIG +GEM versus 6.4 months for GEM [hazard ratio (HR), 1.24; 95% confidence interval (CI) 0.85–1.81]. The median
progression-free survival was 3.4 months for both groups (HR = 0.96; 95% CI 0.68–1.36). The partial response rate was
19% versus 13% for RIG + GEM versus GEM, respectively. Of 64 tumor samples sent for molecular analysis, 47 were
adequate for multiplex genetic testing and 41 were positive for mutations. The majority of cases had KRAS gene muta-
tions (40 cases). Other mutations detected included TP53 (13 cases) and PIK3CA (1 case). No correlation between
mutational status and efficacy was detected.
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Symposium, San Francisco, CA, USA, on 16 January 2015.
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Conclusions: The combination of RIG + GEM failed to demonstrate an improvement in survival or response compared
with GEM in patients with metastatic pancreatic adenocarcinoma. Rigosertib showed a similar safety profile to that seen
in previous trials using the IV formulation.
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introduction
Pancreatic cancer is a devastating disease with limited treatment
options that offer modest benefit in the metastatic setting [1]. In
the United States, pancreatic cancer is the fourth leading cause
of cancer-related death with an estimated 39 590 deaths and
46 420 new diagnoses in 2014 [1]. Approximately 80%–85% of
these patients will have unresectable disease at diagnosis, and
the prognosis is dismal as the 5-year survival rate in the United
States is <6% [1, 2].
Few treatments for advanced pancreatic cancer have shown
efficacy. In 1997, gemcitabine became the standard first-line
therapy in advanced pancreatic cancer based on a phase III
trial demonstrating improved survival with gemcitabine versus
5-fluoruracil (5-FU) (5.65 versus 4.41 months, P = 0.0025) [3].
A subsequent phase III study evaluating the addition of erlotinib
to gemcitabine resulted in a small but significant improvement
in overall survival (OS) versus single-agent gemcitabine (6.24
versus 5.91 months, P = 0.038) [4]. The phase III ACCORD/
PRODIGE trial compared the combination of 5-FU, leucovorin,
oxaliplatin, and irinotecan (FOLFIRINOX) with gemcitabine
alone and showed a significant improvement in median OS
(11.0 versus 6.8 months, respectively; P < 0.0001) [5]. Widespread
use of FOLFIRINOX has certain limitations, including its toxicity
profile (higher incidence of grade 3/4 neutropenia, febrile neutro-
penia, thrombocytopenia, diarrhea, and sensory neuropathy).
More recently, the combination of nab-paclitaxel and gemcita-
bine has been approved for first-line metastatic pancreatic cancer
based on a phase III trial showing improved survival and re-
sponse rates compared with gemcitabine alone (median OS of 8.5
versus 6.7 months, respectively; HR = 0.72; 95% CI 0.62–0.83;
P < 0.001) [6].
The combination of poor prognosis and limited treatment
options with modest efficacy make pancreatic cancer a major
focus in cancer research and treatment. Targeted therapy aimed
at cell-cycle arrest offers a promising approach to improved
treatment efficacy. A potential therapeutic target involved in
pancreatic oncogenesis is the polo-like kinase 1 (PLK1) pathway
[7]. Rigosertib, a first-in-class small-molecule inhibitor of mul-
tiple signaling pathways including phosphoinositide 3-kinase
(PI3K) and PLK1 pathways, showed promising anti-tumor ac-
tivity in solid tumor malignancies, including advanced pancre-
atic cancer in two phase I trials [8, 9]. Rigosertib is believed to
have dual inhibitory activity in the PI3K and PLK1 signaling
pathways, leading to cell-cycle arrest and apoptosis. Recent pre-
clinical data have shown that rigosertib achieves these pleotropic
effects through the inhibition of Ras activity. Specifically, rigo-
sertib appears to bind to the Ras-binding domain (RBD) of
downstream effector kinases such as Raf and PI3K, leading to
their inactivation [10].
Preclinical studies have demonstrated that PLK1 is an import-
ant mitotic checkpoint molecule in G2 DNA damage-induced
arrest, and is involved in multiple steps during mitosis [11].
In addition to PI3K, the PLK1 signaling pathway has been
implicated in treatment resistance in a variety of tumor types
[12, 13]. Jimeno et al. examined 50 different gene expression
profiles in pancreatic adenocarcinoma post-gemcitabine expos-
ure and showed that PLK1 signaling activity was the only gene
that correlated with resistance to gemcitabine [12]. The addition
of rigosertib to in vitro models showed reversal of gemcitabine
resistance. Thus, the addition of rigosertib to gemcitabine may
potentiate the effects of gemcitabine by synergistic inhibition
mitosis promotion through PLK1.
A phase I trial studying rigosertib in combination with gemci-
tabine showed tolerability and efficacy in 40 patients with
advanced solid malignancies [9]. Partial responses were seen in
patients with pancreatic adenocarcinoma, thymic cancer, and
Hodgkin lymphoma. The pharmacokinetic (PK) profile of rigo-
sertib was not altered by gemcitabine. The toxicity profile was
favorable for the combination treatment. The established dose
was rigosertib 1800 mg/m2 as a 2-h continuous intravenous in-
fusion (CIV) infusion on days 1, 4, 8, 11, 15, and 18, and gemci-
tabine 1000 mg/m2 as a 30-min CIV infusion on days 1, 8, and
15 of a 28-day cycle. Owing to these results, rigosertib plus gem-
citabine treatment was further evaluated in patients with meta-
static pancreatic cancer in a phase II/III trial.
materials andmethods
study population
Eligible patients for this study were ≥18 years old with histologically or cyto-
logically confirmed previously untreated metastatic adenocarcinoma of the
pancreas and measurable disease, defined as a lesion ≥20 mm by conven-
tional techniques in at least one dimension or ≥10 mm with spiral computed
tomography (CT) scan. All patients must have had a serum creatinine ≤2.0
mg/dl and transaminase levels no higher than 3.0 times the institutions
upper limit of normal (ULN) unless they had hepatic metastases, in which
they were allowed to have transaminase levels of up to 5.0 times the ULN.
Patients must also have had adequate bone marrow function, an Eastern
Cooperative Oncology Group (ECOG) performance status of ≤2, and a life
expectancy of at least 12 weeks. Written informed consent was obtained
from each patient after institutional review board approval of the clinical
trial.
study design
This open-label, randomized, multicenter study involved 52 sites in multiple
countries. Patients were randomized in a 2:1 fashion to receive either
rigosertib + gemcitabine (RIG + GEM) or gemcitabine only (GEM). Using
permuted block design, the patients were randomized and stratified accord-
ing to ECOG performance status (0–1 versus 2). Dosing in the RIG + GEM
group consisted of rigosertib 1800 mg/m2 via 2-h CIV infusions on days 1, 4,
8, 11, 15, and 18 of a 4-week cycle plus gemcitabine 1000 mg/m2 weekly for
3 weeks of a 4-week cycle. Dosing in the GEM group consisted of gemcita-
bine 1000 mg/m2 weekly for 3 weeks of a 4-week cycle. Patients in the GEM
group were not permitted to cross over to the RIG + GEM group. Palliative
radiotherapy was not allowed during the trial.
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Dose adjustments were made for all non-hematologic grade 3 adverse
events (AEs) or more. Rigosertib dose was reduced to 75% of the starting
dose (1350 mg/m2) after the first grade 3 AE or more and to 50% of the start-
ing dose (900 mg/m2) after the second. Gemcitabine dose was reduced to
750 mg/m2 after the first grade 3 AE or more, and to 600 mg/m2 after the
second. Rigosertib was discontinued after the third occurrence of a grade 3
AE or more, and patients were removed from the study after the third grade
3 AE or more due to gemcitabine.
The use of granulocyte growth factors (G-CSF or GM-CSF), erythropoi-
etin, erythropoietin-like substances, or blood transfusions was permitted at
the discretion of the treating investigator. Imaging and measurement of
CA19-9 were done every 8 weeks after study enrollment. Patients were
treated until disease progression, withdrawal of consent, unacceptable toxici-
ties, or death. AE grading was done using the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI CTCAE), version
4.03. Safety was assessed using AE reports, laboratory tests, vital signs/phys-
ical examination and weight, and toxicity assessments.
tissue collection and biomarker analysis
Archival tissue from resection or biopsy obtained before enrollment in the
study were collected and later analyzed to identify molecular characteristics
and potential biomarkers of treatment susceptibility or resistance. Adequate
tissue samples (minimum 2 mm× 2 mm) in paraffin block from resection or
core biopsy of metastasis or primary tumor were sent to the Colorado
Molecular Correlates Laboratory (CMOCO) for analysis. In cases where only
slides were available, 15 unstained 5-µm sections mounted on slides were
used. CMOCO carried out molecular testing of samples using a multiplex






Total (n = 160)
Demographic and baseline characteristics
ITT population (n = 160)
Age (years)
Mean (range) 63.2 (29–83) 61.8 (30–87) 62.7 (29–87)
Male, n (%) 69/106 (65) 31/54 (57) 100/160 (63)
Hispanic or
Latino, n (%)
7/106 (7) 2/54 (4) 9/160 (6)
Race, n (%)
White 75/106 (71) 39/54 (72) 114/160 (71)
Black or
African American
8 (8) 2 (4) 10 (6)
Asian 20 (19) 13 (24) 33 (21)
Other 3 (3) 0 3 (2)
ECOG performance status, n (%)
0 28/106 (26) 13/54 (24) 41/160 (26)
1 71 (67) 40 (74) 111 (69)
2 7 (7) 1 (2) 8 (5)
Metastasis, n (%) 103/106 (97) 53/54 (98) 156/160 (98)
Liver 88 (83) 48 (89) 136 (85)
Lung 28 (26) 11 (20) 39 (24)
Peritoneum 11 (10) 5 (9) 16 (10)
Retroperitoneal 11 (10) 2 (4) 13 (8)
Weight (kg)
Mean (range) 70.1 (33–110) 68.6 (37–112) 69.6 (33–112)
Assessed for eligibility (n = 204)
Randomized (n = 160)
Allocated to RIG+GEM (n = 106)
• Received treatment (n = 106)
Allocated to GEM (n = 54)
• Received treatment (n = 47)
• Did not receive treatment (6–patient request; 1
AE) (n = 7)
Discontinued treatment (n = 105)
• Progressive disease according to RECIST criteria (n = 46)
• Unacceptable toxicity/adverse event (n = 37)
• Patient request (n = 16)
• Investigator decision (n = 4)
• Non-compliance to protocol (n = 1)
• Intercurrent illness (n = 1)
Deaths from any source (n = 92)
Discontinued treatment (n = 46)
• Progressive disease according to RECIST criteria (n = 28)
• Unacceptable toxicity/adverse event (n = 10)
• Patient request (n = 5)
• Investigator decision (n = 2)
• Non-compliance to protocol (n = 1)
• Intercurrent illness (n = 0)
Deaths from any source (n = 40)
Analyzed in ITT population (n = 106) Analyzed in ITT population (n = 54)
Excluded (n = 44)
• Not meeting inclusion criteria (n = 34)
• Declined to participate (n = 1)
• Other reasons (n = 9)
Figure 1. CONSORT diagram.
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designed to detect >60 point mutations in 15 gene targets, including
PIK3CA, EGFR1, BRAF, KRAS, NRAS, PTEN, TP53, NOTCH1, AKT, APC,
KIT, JAK2, FLT3, CTNNB1, andMEK1.
statistical analysis
The primary end point of this study was OS, defined as the time from study
enrollment until death. The secondary objectives included progression-free
survival (PFS), overall response rate (ORR) using RECIST v.1.1, and safety.
PFS was defined as the time from randomization until disease progression.
Additional secondary objectives involved biomarker analysis (including
PI3K/AKT and PLK1 pathways) carried out on archival tissue from all
patients. The target accrual of 150 patients provided a 90% power to detect a
one-sided P-value of <0.15 and treatment effect size of at least 10 weeks.
Patients were followed until 125 deaths occurred, at which point the un-
adjusted, unstratified log-rank test was used to compare the Kaplan–Meier
survival curves. If the one-sided long-rank P-value was >0.50, the study
would be permanently discontinued for futility. This study was initially
powered for continuation into a phase III trial. The last patient was rando-
mized on 7 March 2013 and the data cut-off date was 9 December 2013.
results
baseline characteristics
Accrual was discontinued after 160 patients were enrolled and
132 deaths had occurred (Table 1 and Figure 1). The last patient
was randomized in March 2013. There remains two patients on-
treatment (one in each arm). The mean age was 62.7 years old
(range 29–87), and 63% of patients were male. Seventy-one
percent were self-reported as Caucasian, followed by 21% Asian,
and 6% Black. ECOG performance status was 0, 1, and 2 in 26%,
69%, and 5%, respectively. There were no major differences in
demographic or tumor characteristics between the two treat-
ment groups. Sixty-four cases were submitted for DNA analysis
using SNaPshot®, and 47 samples were adequate for SNaPshot
testing. The variation between sample submission and adequate
testing was due to insufficient tissue or suboptimal SNaPshot®
analysis.
treatment exposure
The mean duration of treatment was 3.6 cycles (range, 1–14) for
RIG + GEM and 4.0 cycles (range, 1–12) for GEM. In the
RIG + GEM group, 58% of patients had adjustments of the rigo-
sertib dose and 62% required dose adjustments of gemcitabine.
In the GEM group, 47% of patients had dose adjustments.
The mean cumulative dose of gemcitabine was 16.2 g in the
RIG + GEM group and 18.7 g in the GEM group.
Sixty-one patients went on to receive subsequent therapy (38
in the RIG + GEM group versus 23 in the GEM group). Specific
chemotherapy regimens were not captured.
safety
In the RIG + GEM group, the most frequently reported treat-
ment-related non-hematologic AEs were fatigue (27%), nausea
(25%), and hyponatremia (25%) (Table 2). Grade 3 or higher
treatment-related AEs observed more frequently in the RIG +GEM
group were hyponatremia, fatigue, diarrhea, nausea, vomiting, hyo-
pabluminemia, thrombocytopenia, and neutrophil count decreased.
Anemia was the most common hematologic AE reported and was
similar in both groups, followed by neutropenia and thrombocyto-
penia. Only hyponatremia (RIG + GEM = 25%, GEM = 6%) and
AST increased (RIG + GEM = 15%, GEM = 9%) were notably
higher in the RIG + GEM group. Serious AEs were reported in
49 patients (46%) in the RIG + GEM group versus 15 (32%) in
the GEM group. AEs led to the study regimen discontinuation
in 35 patients (33%) in the RIG + GEM group versus 9 (19%) in
the GEM group. Between the first dose and up until 30 days
after the last dose of drug given, there were 17 deaths in the
RIG + GEM group versus 14 in the GEM group.
efficacy
Median OS, the primary end point of the study, was 6.1 months
for RIG + GEM versus 6.4 months for GEM (HR = 1.24, 95% CI
0.85–1.81) (Figure 2a). Median PFS was 3.4 months for both
groups (HR = 0.96, 95% CI 0.68–1.36) (Figure 2b). The overall
best response per RECIST criteria was partial response in 19%
versus 13% of patients for RIG + GEM and GEM, respectively.
Stable disease was found in 50% of patients in the RIG + GEM
group versus 56% in the GEM group. There were no complete
responses in either group. Mutational analysis showed no correl-
ation with efficacy between treatment arms (supplementary



















AEs deemed related to study regimen by NCI CTCAE grade (>10% of
patient population)
Safety population (N = 153)
GI
Nausea 26 (25) 2 (2) 13 (28) 0
Diarrhea 17 (16) 4 (4) 7 (15) 1 (2)
Vomiting 14 (13) 1 (1) 10 (21) 0
Metabolism
Hyponatremia 26 (25) 18 (17) 3 (6) 2 (4)
Decreased appetite 13 (12) 0 5 (11) 0
Hypoalbuminemia 11 (10) 1 (1) 4 (9) 0
Blood
Anemia 30 (28) 8 (8) 13 (28) 2 (4)
Neutropenia 11 (10) 8 (8) 7 (15) 3 (6)
Thrombocytopenia 12 (11) 3 (3) 6 (13) 1 (2)
General
Fatigue 29 (27) 5 (5) 12 (26) 1 (2)
Investigations
ALT increased 15 (14) 1 (1) 5 (11) 1 (2)
increased 16 (15) 1 (1) 4 (9) 1 (2)
Neutrophil count
decreased
13 (12) 10 (9) 5 (11) 2 (4)
Column header counts and denominators are the number of patients
randomized who have received at least one dose of study drug. A patient
is counted at most once in each cell of the table.
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SNaPshot mutational analysis
Of the 64 total cases submitted, 49 samples were prepared for
DNA extraction, 47 of which had adequate tissue to proceed
with testing. Forty-one samples showed detectable mutations
(Figure 3). The majority of cases had KRAS gene mutations (40 of
the 41 samples with mutations). The KRAS mutations detected
included c.35G>A, p.G12D (21 cases), c.35G>T, p.G12V (12 cases),
c.34G>C, p.G12R (4 cases), c.183C>A, p.Q61H (2 cases), and
c.34G>T, p.G12C (1 case). Other mutations detected included TP53
(13 cases) and PIK3CA (1 case). Twelve of the 13 cases with TP53



























BL M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18
106 97 89 80 67 58 54 43 30 28 16 11 10 9 6 2 0 0 0






This portion of the figure





























This portion of the figure
based on very few patients
106 96 67 58 41 37 26 23 12 8 4 3 3 2 1 0 0
54 49 36 29 23 19 15 12 5 2 1 1 1 1 0 0 0
(a)
(b)
Figure 2. (a) OS Kaplan–Meier estimates of OS ITT population (n = 160). (b) PFS Kaplan–Meier estimates of PFS ITT population (n = 160).
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discussion
This was a randomized, open-label, multicenter study of rigoser-
tib, a small-molecule Ras mimetic and inhibitor of the PI3K and
PLK1 pathways, administered in combination with gemcitabine
versus gemcitabine alone in patients with chemo-naïve meta-
static pancreatic adenocarcinoma.
The toxicity profile of the combination arm was similar to
that of the previous phase I study aside from hyponatremia,
which occurred in ∼25% of patients compared with an inci-
dence of ∼5% in phase 1 trials [9]. The etiology of this increased
incidence in hyponatremia remains unclear. Based on previous
phase 1 data, the most common non-hematologic AEs of rigo-
sertib were fatigue, nausea, vomiting, anorexia, and diarrhea.
The most common AEs in the RIG + GEM group included
fatigue, nausea, diarrhea, hyponatremia, and anemia. The hema-
tologic toxicity profile was similar between the two treatment
groups. There were more serious AEs and treatment disconti-
nuations due to AE in the RIG + GEM group.
Targeted mutational analysis demonstrated that the majority of
tumor samples adequate for analysis harbored a KRAS mutation
(40 out of 47 samples). There was a single PIK3CA mutation and
13 TP53 mutations. These findings are consistent with known
genetic mutation profiles in pancreatic cancer, as historically
PIK3CAmutations are rare in pancreatic cancer [14]. Of note, the
testing methodology implemented only tested for known hotspot
mutations, thus other mutations may have been present in
PIK3CA or TP53 which would not have been detected.
Pancreatic cancer is believed to be a KRAS-driven malignancy
[15]. Recent data have shown that rigosertib binds to the RBD
of downstream Ras effector proteins, thus preventing their
activation. In addition, preclinical data in cell lines and patient-
derived xenografts have shown that rigosertib may act synergis-
tically with gemcitabine in resistant pancreatic cancer cell lines
[11, 13, 16]. Due to this, we hypothesized that rigosertib plus
gemcitabine may in fact lead to clinical benefit in an unselected
pancreatic cancer population. However, in our trial, the combin-
ation of rigosertib and gemcitabine did not improve the treat-
ment outcome (median OS of 6.1 versus 6.4 months; HR = 1.24,
95% CI 0.85–1.81).
While the specific mechanisms for the lack of improved effi-
cacy with the combination of rigosertib and gemcitabine in this
study remain unclear, there are likely multiple contributing
factors. For example, independent gain-in-function mutations
of Ras effector proteins would be downstream of rigosertib
intervention. Furthermore, while mutations such as KRAS occur
in up to 90% of pancreatic adenocarcinomas, multiple studies
have identified human pancreatic cancer cells with varying
levels of sensitivity to KRAS inactivation [17, 18]. Strong evi-
dence for this concept comes from a recent study in which
investigators classified tumors from pancreatic cancer patients
into three distinct subtypes based on gene expression profiles:
‘classical’ (41.2%), ‘quasi-mesenchymal’ (36.5%), and ‘exocrine-
like’ (22.3%) [18]. The relationship between KRAS dependence
and subtype was explored using KRAS RNAi. Importantly, ‘clas-
sical’ tumors proved to be more dependent upon KRAS than the
other subtypes, suggesting that inhibition of this highly mutated
oncogene may only be effective in a subset of pancreatic cancer
patients. This and other studies highlight the inherent hetero-
geneity of pancreatic cancer and may help to explain the lack of
clinical activity for rigosertib in KRAS mutant pancreatic cancer
patients. Finally, while no detailed PK data were collected in this
study, the dosages and administration of gemcitabine and rigo-
sertib were based on phase I PK data and we believe that PK s
are unlikely to explain the results from this study [8].
Multiple trials investigating rigosertib as a single agent and
in combination for hematologic malignancies including myelo-
dysplastic syndromes (MDSs) have shown promising results
[19–21]. The reasons for the difference in clinical efficacy between
pancreatic cancer and MDS remain unclear. In a recent study
by Hyoda et al., rigosertib was shown to induce apoptosis in
MDS cancer cells lines through the inhibition of the PI3K/Akt
pathway and promoted the phosphorylation of histone H2AX
leading to DNA damage-induced G2/M arrest [22]. This argues
that at least a portion of MDS cases may rely on the PI3K/Akt
pathway for oncogenesis, and this inhibition may lead to induc-
tion of apoptosis and improved clinical outcomes. In contrast,
pancreatic cancer may achieve resistance through aberrant
protein upregulation in alternative pathways, such as c-MET and
HER-2, that in turn activate the RAS pathway downstream of
KRAS inhibition by rigosertib.
Clinical trials using rigosertib in MDSs and other hematologic
neoplasms are ongoing. Based on the results of our trial, there
are no current plans to perform further trials with the use of
rigosertib in pancreatic cancer. Rigosertib was well tolerated and
exhibited a similar safety profile to that observed in other trials
using the IV formulation.
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Figure 3. Mutation analysis—41 samples positive for a mutation.
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